The Role of Cyanidin-3-
colorectal cancer
cyanidin-3-O-glucoside
epithelial-mesenchymal transition
oxaliplatin resistance
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
07 Nov 2023
07 Nov 2023
Historique:
received:
25
09
2023
revised:
11
10
2023
accepted:
16
10
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Epithelial-mesenchymal transition (EMT) plays an important role in the biological and biochemical processes of cells, and it is a critical process in the malignant transformation, and mobility of cancer. Additionally, EMT is one of the main mechanisms contributing to chemoresistance. Resistance to oxaliplatin (OXA) poses a momentous challenge in the chemotherapy of advanced colorectal cancer (CRC) patients, highlighting the need to reverse drug resistance and improve patient survival. In this study, we explored the response of cyanidin-3- We generated an acquired OXA-resistant cell line, named HCT-116-ROx, by gradually exposing parental HCT-116 cells to increasing concentrations of OXA. To characterize the resistance, we performed cytotoxicity assays and shape factor analyses. The apoptotic rate of both resistant and parental cells was determined using Hoechst 33342/Propidium Iodide (PI) fluorescence staining. Migration capacity was evaluated using a wound-healing assay. The mesenchymal phenotype was assessed through qRT-PCR and immunofluorescence staining, employing E-cadherin, N-cadherin, and Vimentin markers. Resistance characterization announced decreased OXA sensitivity in resistant cells compared to parental cells. Moreover, the resistant cells exhibited a spindle cell morphology, indicative of the mesenchymal phenotype. Combined treatment of C3G and OXA resulted in an augmented apoptotic rate in the resistant cells. The migration capacity of resistant cells was higher than parental cells, while treatment with C3G decreased the migration rate of HCT-116-ROx cells. Analysis of EMT markers showed that HCT-116-ROx cells exhibited loss of the epithelial phenotype (E-cadherin) and gain of the mesenchymal phenotype (N-cadherin and Vimentin) compared to HCT-116 cells. However, treatment of resistant cells with C3G reversed the mesenchymal phenotype. The morphological observations of cells acquiring oxaliplatin resistance indicated the loss of the epithelial phenotype and the acquisition of the mesenchymal phenotype. These findings suggest that EMT may contribute to acquired OXA resistance in CRC. Furthermore, C3G decreased the mobility of resistant cells, and reversed the EMT process, indicating its potential to overcome acquired OXA resistance.
Sections du résumé
BACKGROUND
BACKGROUND
Epithelial-mesenchymal transition (EMT) plays an important role in the biological and biochemical processes of cells, and it is a critical process in the malignant transformation, and mobility of cancer. Additionally, EMT is one of the main mechanisms contributing to chemoresistance. Resistance to oxaliplatin (OXA) poses a momentous challenge in the chemotherapy of advanced colorectal cancer (CRC) patients, highlighting the need to reverse drug resistance and improve patient survival. In this study, we explored the response of cyanidin-3-
METHODS
METHODS
We generated an acquired OXA-resistant cell line, named HCT-116-ROx, by gradually exposing parental HCT-116 cells to increasing concentrations of OXA. To characterize the resistance, we performed cytotoxicity assays and shape factor analyses. The apoptotic rate of both resistant and parental cells was determined using Hoechst 33342/Propidium Iodide (PI) fluorescence staining. Migration capacity was evaluated using a wound-healing assay. The mesenchymal phenotype was assessed through qRT-PCR and immunofluorescence staining, employing E-cadherin, N-cadherin, and Vimentin markers.
RESULTS
RESULTS
Resistance characterization announced decreased OXA sensitivity in resistant cells compared to parental cells. Moreover, the resistant cells exhibited a spindle cell morphology, indicative of the mesenchymal phenotype. Combined treatment of C3G and OXA resulted in an augmented apoptotic rate in the resistant cells. The migration capacity of resistant cells was higher than parental cells, while treatment with C3G decreased the migration rate of HCT-116-ROx cells. Analysis of EMT markers showed that HCT-116-ROx cells exhibited loss of the epithelial phenotype (E-cadherin) and gain of the mesenchymal phenotype (N-cadherin and Vimentin) compared to HCT-116 cells. However, treatment of resistant cells with C3G reversed the mesenchymal phenotype.
CONCLUSION
CONCLUSIONS
The morphological observations of cells acquiring oxaliplatin resistance indicated the loss of the epithelial phenotype and the acquisition of the mesenchymal phenotype. These findings suggest that EMT may contribute to acquired OXA resistance in CRC. Furthermore, C3G decreased the mobility of resistant cells, and reversed the EMT process, indicating its potential to overcome acquired OXA resistance.
Identifiants
pubmed: 38004099
pii: nu15224705
doi: 10.3390/nu15224705
pmc: PMC10674439
pii:
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
cyanidin
7732ZHU564
Anthocyanins
0
Vimentin
0
Cadherins
0
Glucosides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Dokuz Eylul University Scientific Research Coordination Unit
ID : 2020.KB.SAG.039
Références
Sci Rep. 2019 Aug 9;9(1):11560
pubmed: 31399602
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Onco Targets Ther. 2019 May 17;12:3893-3903
pubmed: 31190888
BMC Complement Med Ther. 2020 Oct 15;20(1):312
pubmed: 33059637
Theranostics. 2021 Mar 4;11(10):4839-4857
pubmed: 33754031
Front Oncol. 2021 Jun 04;11:649029
pubmed: 34150617
Mol Med Rep. 2019 Sep;20(3):2339-2346
pubmed: 31322179
Molecules. 2020 Aug 21;25(17):
pubmed: 32825684
Crit Rev Oncol Hematol. 2019 Apr;136:20-30
pubmed: 30878125
Drug Resist Updat. 2020 Dec;53:100715
pubmed: 32679188
Nat Cell Biol. 2008 Feb;10(2):127-37
pubmed: 18204440
Elife. 2021 Aug 03;10:
pubmed: 34342264
Dev Cell. 2019 May 6;49(3):361-374
pubmed: 31063755
Food Res Int. 2018 Jul;109:232-249
pubmed: 29803446
Nature. 2015 Nov 26;527(7579):525-530
pubmed: 26560028
J Biomol Struct Dyn. 2019 Sep;37(14):3838-3847
pubmed: 30282523
Biomed Pharmacother. 2020 Aug;128:110329
pubmed: 32502843
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Adv Exp Med Biol. 2018;1095:101-110
pubmed: 30229551
Food Funct. 2019 May 22;10(5):2871-2880
pubmed: 31070214
Molecules. 2016 Jul 22;21(7):
pubmed: 27455225
Front Pharmacol. 2020 Mar 20;11:343
pubmed: 32265714
Nutrients. 2021 Jun 21;13(6):
pubmed: 34205642
Front Oncol. 2021 Jan 22;10:585452
pubmed: 33552961
Onco Targets Ther. 2020 Feb 21;13:1625-1635
pubmed: 32110058
Adv Nutr. 2015 Sep 15;6(5):620-2
pubmed: 26374184
Front Pharmacol. 2022 Aug 25;13:969422
pubmed: 36091779
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):725-736
pubmed: 30861353
Biomed Pharmacother. 2021 Jan;133:110909
pubmed: 33227701
World J Gastroenterol. 2018 Sep 14;24(34):3834-3848
pubmed: 30228778
Crit Rev Food Sci Nutr. 2019;59(6):982-991
pubmed: 30595029
Food Nutr Res. 2020 Sep 28;64:
pubmed: 33240028
Int J Mol Sci. 2019 Jul 24;20(15):
pubmed: 31344863
Adv Nutr. 2020 Mar 1;11(2):224-236
pubmed: 31329250
Curr Drug Targets. 2017;18(6):629-640
pubmed: 26424400
Visc Med. 2016 Jun;32(3):156-7
pubmed: 27493941
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Arch Pharm Res. 2019 Jan;42(1):14-24
pubmed: 30649699
Food Nutr Res. 2017 Aug 13;61(1):1361779
pubmed: 28970777
Anticancer Drugs. 2018 Apr;29(4):334-340
pubmed: 29420338
J Cell Physiol. 2018 Jul;233(7):5458-5467
pubmed: 29247488
World J Gastroenterol. 2021 Apr 14;27(14):1435-1450
pubmed: 33911466
Oncol Lett. 2017 Jul;14(1):647-654
pubmed: 28693217
Nat Rev Cancer. 2021 Jan;21(1):37-50
pubmed: 33128031
Mol Cancer Ther. 2015 Aug;14(8):1767-76
pubmed: 26184483
FASEB J. 2020 Feb;34(2):2227-2237
pubmed: 31916632
Front Oncol. 2019 Oct 22;9:1110
pubmed: 31696058
Oncol Res. 2020 Sep 1;28(4):423-438
pubmed: 32331534
Phytother Res. 2019 Jan;33(1):81-89
pubmed: 30251280
Food Funct. 2019 Feb 20;10(2):592-601
pubmed: 30672917
Cell Physiol Biochem. 2018;51(5):2148-2159
pubmed: 30522111
Crit Rev Food Sci Nutr. 2006;46(2):161-83
pubmed: 16431408
Front Oncol. 2020 Apr 07;10:499
pubmed: 32318352